Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 5076-5085
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5076
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5076
Table 3 Histopathological features, treatments, and outcome of 16 transplant patients with gastrointestinal stromal tumor
Ref. | Size (mm) | Mitotic count | Fletcher’s criteria | Joensuu’s criteria | Mutation identified | Resection | Initial adjuvant treatment | Second line treatment | Outcome |
Agaimy and Wünsch[11] | 35 | < 5/50 | Low | Low | Not described | Yes | No | Not described | Alive and relapse free at 68 mo |
Agaimy and Wünsch[11] | 230 | 14/50 | High | High | Not described | Yes | No | Not described | Not described |
Saidi et al[19] | 25 | 1/50 | Low | High | Not described | Yes | No | Not described | Alive and relapse free at 18 mo |
Camargo et al[22] | 50 | 5/50 | Intermediate | High | Not described | Yes | No | Not described | Alive and relapse free at 20 mo |
Tu et al[18] | 45 | 2-3/50 | Low | Low | PDGFRA exon 18 V824V | Yes | No | Not described | Alive and relapse free 24 mo |
Mulder et al[12] | 50 | > 10/50 | High | High | Not described | Yes | No | Imatinib 400 mg/d then 200 mg/d | Died 44 mo |
Mrzljak et al[20] | 10 | 1/50 | Very low | Very low | Not described | Yes | No | No | Died 3 yr after from acute leukemia |
Cimen et al[13] | 150 | 14/50 | High | High | KIT T574del | Yes | Imatinib 400 mg/d | Not described | Alive and relapse free at 12 mo |
Cheung et al[14] | 30 | 9/50 | Intermediate | Intermediate | Not described | Yes | No | No | Died from pneumonia at 2 yr |
Cheung et al[14] | Not described | Not described | Not described | Not described | Not described | No | Imatinib 400 mg/d for 1 yr | Switch CsA to sirolimus | Alive and relapse free at 10 yr |
Patiño et al[15] | 58 | Not described | Intermediate or high | Intermediate of high | Not described | Yes | No | Imatinib 400 mg/d | Alive and relapse free/5 yr after imatinib initiation |
Xie et al[21] | 10 | < 5/50 | Very low | Very low | KIT exon 11 | Yes | No | No | Not described |
Elkabets et al[17] | 31 | Not described | Not described | Not described | Not described | Yes | No | No | Alive and relapse free at 40 mo |
Takahashi et al[16] | 110 | 20/50 | High | High | KIT exon 11 | Yes | Imatinib 400 mg/d reduced to 3000 mg/d | No | Alive and relapse free at 18 mo |
Stammler et al | 27 | 2/5 | Low | Low | KIT exon 11 | Yes | No | No | Alive and relapse free at 2 mo |
Stammler et al | 51 | 10/50 | High | High | PDGFRA exon 18 | Yes | No | Sunitinib then regorafenib then dasatinib | Died 56 mo later |
- Citation: Stammler R, Anglicheau D, Landi B, Meatchi T, Ragot E, Thervet E, Lazareth H. Gastrointestinal tumors in transplantation: Two case reports and review of literature . World J Gastroenterol 2022; 28(34): 5076-5085
- URL: https://www.wjgnet.com/1007-9327/full/v28/i34/5076.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i34.5076